Micromet's cancer drug portfolio draws big drugmakers' attention

06/14/2010 | Bloomberg Businessweek

Biotech firm Micromet was able to secure a partnership with major drugmakers, including Bayer and Boehringer Ingelheim, because of its line of cancer treatments that might boost the effectiveness of rival medicines. Blinatumomab, Micromet's drug candidate for acute lymphocytic leukemia, led to complete remission during a clinical trial in about 80% of patients who still had leukemia cells after undergoing different forms of chemotherapy.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX